{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:19:38Z","timestamp":1788272378247,"version":"build-2803163510"},"reference-count":183,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005046","name":"Natural Science Foundation of Heilongjiang Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005046","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nutr."],"abstract":"<jats:p>Glucagon-like peptide-1 receptor agonists and dual agonists of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, exemplified by semaglutide and tirzepatide, respectively, have reshaped care for obesity-related heart failure with preserved ejection fraction (HFpEF). Their benefits extend beyond weight reduction to symptoms and physical function and, for tirzepatide, a lower risk of worsening heart failure. Yet kilograms lost do not reveal whether treatment preferentially reduces harmful adiposity, preserves muscle function, or maintains nutritional adequacy. Against this background, we examine how medical nutrition therapy (MNT) can be integrated with incretin-based therapy to support high-quality weight loss\u2014a working construct used here to denote loss of excess adiposity without avoidable compromise of nutritional status or functional reserve. The discussion centers on three linked questions: how appetite suppression and gastrointestinal intolerance alter nutritional risk; how body composition relates to muscle and patient-centered outcomes; and how nutrition care should evolve from treatment initiation through plateau, maintenance, and discontinuation. Available evidence supports early nutrition assessment, attention to protein and overall diet quality, and coordinated resistance and aerobic exercise, while showing that body composition cannot replace direct assessment of strength, walking capacity, symptoms, and health status. We therefore outline a phase-based MNT pathway for obesity-related HFpEF, while emphasizing that no randomized trial has tested a protocolized nutrition program alongside incretin-based therapy in this population. The next advance should be judged not only by the amount of weight lost, but by whether that loss is safe, function-preserving, durable, and meaningful to patients.<\/jats:p>","DOI":"10.3389\/fnut.2026.1914155","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T04:22:22Z","timestamp":1786681342000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Medical nutrition therapy in incretin-treated obesity-related heart failure with preserved ejection fraction"],"prefix":"10.3389","volume":"13","author":[{"given":"Qiuli","family":"Ming","sequence":"first","affiliation":[{"name":"The Third Affiliated Hospital of Henan Medical University","place":["Xinxiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze","family":"Li","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital and College of Clinical Medicine, Henan University of Science and Technology","place":["Luoyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1016\/j.jacc.2023.01.049","article-title":"Heart failure with preserved ejection fraction","volume":"81","author":"Borlaug","year":"2023","journal-title":"J Am Coll Cardiol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/j.jacc.2023.03.393","article-title":"2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"81","author":"Kittleson","year":"2023","journal-title":"J Am Coll Cardiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1002\/ejhf.3676","article-title":"Heart failure and obesity: translational approaches and therapeutic perspectives. A scientific statement of the heart failure association of the ESC","volume":"27","author":"Savarese","year":"2025","journal-title":"Eur J Heart Fail."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1016\/j.jacc.2025.05.008","article-title":"2025 ACC scientific statement on the management of obesity in adults with heart failure: a report of the American College of Cardiology","volume":"86","author":"Kittleson","year":"2025","journal-title":"J Am Coll Cardiol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S2213-8587(24)00316-4","article-title":"Definition and diagnostic criteria of clinical obesity","volume":"13","author":"Rubino","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1038\/s41591-024-03095-3","article-title":"A new framework for the diagnosis, staging and management of obesity in adults","volume":"30","author":"Busetto","year":"2024","journal-title":"Nat Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1093\/eurheartj\/ehaf057","article-title":"Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trial","volume":"46","author":"Peikert","year":"2025","journal-title":"Eur Heart J."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/j.jacc.2025.08.012","article-title":"Adiposity-related anthropometrics and clinical outcomes in heart failure with mildly reduced or preserved ejection fraction","volume":"86","author":"Ostrominski","year":"2025","journal-title":"J Am Coll Cardiol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/j.jchf.2024.06.006","article-title":"Obesity and weight loss strategies for patients with heart failure","volume":"12","author":"Vest","year":"2024","journal-title":"JACC Heart Fail."},{"key":"B10","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/s41573-025-01183-8","article-title":"GLP-1-based therapies for diabetes, obesity and beyond","volume":"24","author":"Drucker","year":"2025","journal-title":"Nat Rev Drug Discov."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1056\/NEJMoa2410819","article-title":"Tirzepatide for obesity treatment and diabetes prevention","volume":"392","author":"Jastreboff","year":"2025","journal-title":"N Engl J Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/S0140-6736(24)01498-3","article-title":"Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial","volume":"404","author":"Deanfield","year":"2024","journal-title":"Lancet."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.jacc.2025.06.058","article-title":"Influence of type 2 diabetes on the effects of tirzepatide in patients with heart failure and a preserved ejection fraction with obesity","volume":"86","author":"Packer","year":"2025","journal-title":"J Am Coll Cardiol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"103363","DOI":"10.1016\/j.eclinm.2025.103363","article-title":"The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions","volume":"86","author":"Moiz","year":"2025","journal-title":"eClinicalMedicine"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1016\/S0140-6736(24)00469-0","article-title":"Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials","volume":"403","author":"Butler","year":"2024","journal-title":"Lancet."},{"key":"B20","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.ajcnut.2025.04.023","article-title":"Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society","volume":"122","author":"Mozaffarian","year":"2025","journal-title":"Am J Clin Nutr."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e13841","DOI":"10.1111\/obr.13841","article-title":"Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity","volume":"26","author":"Mechanick","year":"2025","journal-title":"Obes Rev."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1161\/CIRCULATIONAHA.124.067676","article-title":"Muscle mass and glucagon-like peptide-1 receptor agonists: adaptive or maladaptive response to weight loss?","volume":"150","author":"Linge","year":"2024","journal-title":"Circulation"},{"key":"B23","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/S2213-8587(24)00272-9","article-title":"Muscle matters: the effects of medically induced weight loss on skeletal muscle","volume":"12","author":"Prado","year":"2024","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/S2213-8587(25)00122-6","article-title":"Body composition during major incretin-based weight loss","volume":"13","author":"Dirksen","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"102610","DOI":"10.1016\/j.jchf.2025.102610","article-title":"Frailty and effects of semaglutide in obesity-related HFpEF","volume":"13","author":"Pandey","year":"2025","journal-title":"JACC Heart Fail."},{"key":"B26","doi-asserted-by":"publisher","first-page":"102660","DOI":"10.1016\/j.jchf.2025.102660","article-title":"Semaglutide and exercise function in obesity-related HFpEF","volume":"13","author":"Borlaug","year":"2025","journal-title":"JACC Heart Fail."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1093\/eurheartj\/ehag201","article-title":"Fat, muscle, and anti-obesity medications in cardiovascular disease prevention","volume":"47","author":"Khan","year":"2026","journal-title":"Eur Heart J."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.2337\/dbi25-0003","article-title":"High-quality weight loss in obesity: importance of skeletal muscle","volume":"74","author":"Harper","year":"2025","journal-title":"Diabetes"},{"key":"B29","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/S0140-6736(24)01210-8","article-title":"Obesity in adults","volume":"404","author":"Lingvay","year":"2024","journal-title":"Lancet."},{"key":"B30","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1001\/jamainternmed.2023.7733","article-title":"Body composition in anti-obesity medication trials\u2014beyond scales","volume":"184","author":"Agarwal","year":"2024","journal-title":"JAMA Intern Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1038\/s41591-023-02526-x","article-title":"Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial","volume":"29","author":"Borlaug","year":"2023","journal-title":"Nat Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.jacc.2025.04.059","article-title":"Impact of body mass index, central adiposity, and weight loss on the benefits of tirzepatide in HFpEF","volume":"86","author":"Borlaug","year":"2025","journal-title":"J Am Coll Cardiol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.jacc.2024.11.001","article-title":"Tirzepatide reduces LV mass and paracardiac adipose tissue in obesity-related heart failure","volume":"85","author":"Kramer","year":"2025","journal-title":"J Am Coll Cardiol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.1038\/s41591-025-03765-w","article-title":"Framework for the pharmacological treatment of obesity and its complications from the European association for the study of obesity (EASO)","volume":"31","author":"McGowan","year":"2025","journal-title":"Nat Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s13679-026-00706-7","article-title":"Beyond the scale: setting goals for outcomes beyond weight in evidence-based obesity treatment","volume":"15","author":"Schumacher","year":"2026","journal-title":"Curr Obes Rep."},{"key":"B36","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.ajcnut.2025.06.020","article-title":"Definitions matter in body composition science","volume":"122","author":"Potter","year":"2025","journal-title":"Am J Clin Nutr."},{"key":"B37","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.ajcnut.2025.05.022","article-title":"Methodological standards for body composition\u2014an expert-endorsed guide for research and clinical applications: levels, models, and terminology","volume":"122","author":"Prado","year":"2025","journal-title":"Am J Clin Nutr."},{"key":"B38","doi-asserted-by":"publisher","first-page":"100335","DOI":"10.1016\/j.advnut.2024.100335","article-title":"Are lean body mass and fat-free mass the same or different body components? A critical perspective","volume":"15","author":"Heymsfield","year":"2024","journal-title":"Adv Nutr."},{"key":"B39","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s13679-024-00593-w","article-title":"Updates on methods for body composition analysis: implications for clinical practice","volume":"14","author":"Thomas","year":"2025","journal-title":"Curr Obes Rep."},{"key":"B40","doi-asserted-by":"publisher","first-page":"e70184","DOI":"10.1002\/jcsm.70184","article-title":"Reference methods for measuring skeletal muscle mass: a critical perspective","volume":"17","author":"Heymsfield","year":"2026","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"B41","doi-asserted-by":"publisher","first-page":"101283","DOI":"10.1016\/j.ajcnut.2026.101283","article-title":"Methodological standards for body composition assessment\u2014an expert-endorsed guide for research and clinical applications: bioimpedance, dual-energy X-ray absorptiometry, computerized tomography, and ultrasound methods","volume":"123","author":"Prado","year":"2026","journal-title":"Am J Clin Nutr."},{"key":"B42","doi-asserted-by":"publisher","first-page":"e13760","DOI":"10.1002\/jcsm.13760","article-title":"Impact of muscle quality on muscle strength and physical performance beyond muscle mass or diabetes status","volume":"16","author":"Kim","year":"2025","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e70000","DOI":"10.1002\/jcsm.70000","article-title":"Impact of adipose tissue and lipids on skeletal muscle in sarcopenia","volume":"16","author":"Jang","year":"2025","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"B44","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1111\/dom.16275","article-title":"Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight","volume":"27","author":"Look","year":"2025","journal-title":"Diabetes Obes Metab."},{"key":"B45","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/dom.70141","article-title":"Impact of semaglutide on fat mass, lean mass and muscle function in patients with obesity: the SEMALEAN study","volume":"28","author":"Alissou","year":"2026","journal-title":"Diabetes Obes Metab."},{"key":"B46","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1001\/jama.2024.6586","article-title":"Is weight loss\u2013induced muscle mass loss clinically relevant?","volume":"332","author":"Conte","year":"2024","journal-title":"JAMA."},{"key":"B47","doi-asserted-by":"publisher","first-page":"e70147","DOI":"10.1002\/jcsm.70147","article-title":"Muscle loss in obesity therapy as a therapeutic target: trial design and endpoints for regulatory discussions","volume":"16","author":"Von Haehling","year":"2025","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"B48","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1056\/NEJMcp2305181","article-title":"Heart failure with preserved ejection fraction","volume":"392","author":"Cannata","year":"2025","journal-title":"N Engl J Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s10741-025-10504-3","article-title":"Mechanisms of exercise intolerance in heart failure with preserved ejection fraction (HFpEF)","volume":"30","author":"Pecchia","year":"2025","journal-title":"Heart Fail Rev."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/j.jchf.2023.05.018","article-title":"Distinct impact of noncardiac comorbidities on exercise capacity and functional status in chronic heart failure","volume":"11","author":"Martens","year":"2023","journal-title":"JACC Heart Fail."},{"key":"B51","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1002\/ejhf.3105","article-title":"Clinical phenogroup diversity and multiplicity: impact on mechanisms of exercise intolerance in heart failure with preserved ejection fraction","volume":"26","author":"Larson","year":"2024","journal-title":"Eur J Heart Fail."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1161\/CIRCULATIONAHA.123.065909","article-title":"Excess pericardial fat is related to adverse cardio-mechanical interaction in heart failure with preserved ejection fraction","volume":"148","author":"Zamani","year":"2023","journal-title":"Circulation"},{"key":"B53","doi-asserted-by":"publisher","first-page":"e011693","DOI":"10.1161\/CIRCHEARTFAILURE.123.011693","article-title":"Identifying the mechanisms of a peripherally limited exercise phenotype in patients with heart failure with preserved ejection fraction","volume":"17","author":"Skow","year":"2024","journal-title":"Circ Heart Fail."},{"key":"B54","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1001\/jamacardio.2023.0957","article-title":"Skeletal muscle mitochondrial respiration and exercise intolerance in patients with heart failure with preserved ejection fraction","volume":"8","author":"Scandalis","year":"2023","journal-title":"JAMA Cardiol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"e012512","DOI":"10.1161\/CIRCHEARTFAILURE.124.012512","article-title":"Skeletal muscle quantity versus quality in heart failure: exercise intolerance and outcomes in older patients with HFpEF are related to abnormal skeletal muscle metabolism rather than age-related skeletal muscle loss","volume":"18","author":"Lewsey","year":"2025","journal-title":"Circ Heart Fail."},{"key":"B56","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.jchf.2022.11.015","article-title":"Patient-reported frailty and functional status in heart failure with preserved ejection fraction","volume":"11","author":"Kaul","year":"2023","journal-title":"JACC Heart Fail."},{"key":"B57","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1161\/CIRCULATIONAHA.124.072679","article-title":"Effects of tirzepatide on the clinical trajectory of patients with heart failure, preserved ejection fraction, and obesity","volume":"151","author":"Zile","year":"2025","journal-title":"Circulation"},{"key":"B58","doi-asserted-by":"publisher","first-page":"102478","DOI":"10.1016\/j.jchf.2025.02.024","article-title":"Transferrin saturation is a better predictor than ferritin of metabolic and hemodynamic exercise responses in HFpEF","volume":"13","author":"Lee","year":"2025","journal-title":"JACC Heart Fail."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.2337\/dci24-0003","article-title":"Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity","volume":"47","author":"Drucker","year":"2024","journal-title":"Diabetes Care"},{"key":"B60","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1038\/s41591-025-03774-9","article-title":"Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial","volume":"31","author":"Martin","year":"2025","journal-title":"Nat Med."},{"key":"B61","doi-asserted-by":"publisher","first-page":"4480","DOI":"10.1111\/dom.15802","article-title":"Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: a randomized controlled trial","volume":"26","author":"Gabe","year":"2024","journal-title":"Diabetes Obes Metab."},{"key":"B62","doi-asserted-by":"publisher","first-page":"6784","DOI":"10.1111\/dom.70063","article-title":"Impact of tirzepatide treatment on participant-reported food craving and food preference: secondary analyses of a phase 1 randomised controlled trial in people with obesity with dietary restriction","volume":"27","author":"Kennedy","year":"2025","journal-title":"Diabetes Obes Metab."},{"key":"B63","doi-asserted-by":"publisher","first-page":"5008","DOI":"10.1111\/dom.16548","article-title":"Real-world insights into incretin-based therapy: associations between changes in taste perception and appetite regulation in individuals with obesity and overweight: a cross-sectional study","volume":"27","author":"Kapan","year":"2025","journal-title":"Diabetes Obes Metab."},{"key":"B64","doi-asserted-by":"publisher","first-page":"e2555449","DOI":"10.1001\/jamanetworkopen.2025.55449","article-title":"Consumer food purchases after glucagon-like peptide-1 receptor agonist initiation","volume":"9","author":"S\u00f8rensen","year":"2026","journal-title":"JAMA Netw Open"},{"key":"B65","doi-asserted-by":"publisher","first-page":"3318","DOI":"10.3390\/nu17213318","article-title":"Exploring dietary intake in adults with type 2 diabetes using GLP-1 receptor agonists: a cross-sectional analysis","volume":"17","author":"Ponzo","year":"2025","journal-title":"Nutrients"},{"key":"B66","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41366-025-01952-w","article-title":"Bridging the nutrition guidance gap for GLP-1 receptor agonist therapy assisted weight loss: lessons from bariatric surgery","volume":"50","author":"Spreckley","year":"2026","journal-title":"Int J Obes."},{"key":"B67","doi-asserted-by":"publisher","first-page":"3659","DOI":"10.3390\/nu17233659","article-title":"Macronutrient, micronutrient supplementation and monitoring for patients on GLP-1 agonists: can we learn from metabolic and bariatric surgery?","volume":"17","author":"Sibal","year":"2025","journal-title":"Nutrients"},{"key":"B68","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S2468-1253(24)00188-2","article-title":"Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions","volume":"9","author":"Jalleh","year":"2024","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/dom.14551","article-title":"Gastrointestinal tolerability of once-weekly semaglutide 2","volume":"24","author":"Wharton","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"B70","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as compared with semaglutide for the treatment of obesity","volume":"393","author":"Aronne","year":"2025","journal-title":"N Engl J Med."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1038\/s41366-025-01859-6","article-title":"Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis","volume":"49","author":"Ismaiel","year":"2025","journal-title":"Int J Obes."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1053\/j.gastro.2025.06.003","article-title":"Glucagon-like peptide-1 receptor agonists and gastrointestinal adverse events: a systematic review and meta-analysis","volume":"169","author":"Chiang","year":"2025","journal-title":"Gastroenterology"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1566498","DOI":"10.3389\/fnut.2025.1566498","article-title":"Investigating nutrient intake during use of glucagon-like peptide-1 receptor agonist: a cross-sectional study","volume":"12","author":"Johnson","year":"2025","journal-title":"Front Nutr."},{"key":"B74","doi-asserted-by":"publisher","first-page":"100195","DOI":"10.1016\/j.obpill.2025.100195","article-title":"Diet quality and nutrient distribution while using glucagon-like-peptide-1 receptor agonist: a secondary cross-sectional analysis","volume":"16","author":"Johnson","year":"2025","journal-title":"Obes Pillars"},{"key":"B75","doi-asserted-by":"publisher","first-page":"3542","DOI":"10.1111\/dom.16368","article-title":"The effect of semaglutide on intestinal iron absorption in patients with type 2 diabetes mellitus\u2014a pilot study","volume":"27","author":"Melis","year":"2025","journal-title":"Diabetes Obes Metab."},{"key":"B76","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.1111\/jgs.18590","article-title":"Malnutrition in heart failure with preserved ejection fraction","volume":"71","author":"Zainul","year":"2023","journal-title":"J Am Geriatr Soc."},{"key":"B77","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.3390\/nu17142361","article-title":"High-protein dietary interventions in heart failure: a systematic review of clinical and functional outcomes","volume":"17","author":"Evangelista","year":"2025","journal-title":"Nutrients"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1428010","DOI":"10.3389\/fnut.2024.1428010","article-title":"Dietary strategies and nutritional supplements in the management of heart failure: a systematic review","volume":"11","author":"Yu","year":"2024","journal-title":"Front Nutr."},{"key":"B79","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","volume":"28","author":"Garvey","year":"2022","journal-title":"Nat Med."},{"key":"B80","doi-asserted-by":"publisher","first-page":"102624","DOI":"10.1016\/j.eclinm.2024.102624","article-title":"Once-weekly semaglutide versus placebo in adults with increased fracture risk: a randomised, double-blinded, two-centre, phase 2 trial","volume":"72","author":"Hansen","year":"2024","journal-title":"eClinicalMedicine"},{"key":"B81","doi-asserted-by":"publisher","first-page":"e2416775","DOI":"10.1001\/jamanetworkopen.2024.16775","article-title":"Bone health after exercise alone, GLP-1 receptor agonist treatment, or combination treatment: a secondary analysis of a randomized clinical trial","volume":"7","author":"Jensen","year":"2024","journal-title":"JAMA Netw Open"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1210\/clinem\/dgag052","article-title":"Skeletal effect of semaglutide and tirzepatide in patients with increased risk of fractures","volume":"111","author":"Liu","year":"2026","journal-title":"J Clin Endocrinol Metab"},{"key":"B83","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/S2213-8587(25)00027-0","article-title":"Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial","volume":"13","author":"Sattar","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/S2213-8587(25)00092-0","article-title":"Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial","volume":"13","author":"Coskun","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"e2413172","DOI":"10.1001\/jamanetworkopen.2024.13172","article-title":"GLP-1 receptor agonist discontinuation among patients with obesity and\/or type 2 diabetes","volume":"7","author":"Do","year":"2024","journal-title":"JAMA Netw Open"},{"key":"B86","doi-asserted-by":"publisher","first-page":"e2457349","DOI":"10.1001\/jamanetworkopen.2024.57349","article-title":"Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among US adults with overweight or obesity","volume":"8","author":"Rodriguez","year":"2025","journal-title":"JAMA Netw Open"},{"key":"B87","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial","volume":"331","author":"Aronne","year":"2024","journal-title":"JAMA"},{"key":"B88","doi-asserted-by":"publisher","first-page":"103680","DOI":"10.1016\/j.eclinm.2025.103680","article-title":"Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis","volume":"90","author":"Tzang","year":"2025","journal-title":"eClinicalMedicine"},{"key":"B89","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s11154-025-09963-8","article-title":"Weight cycling and its effects on muscle mass, sarcopenia and sarcopenic obesity","volume":"26","author":"Zamboni","year":"2025","journal-title":"Rev Endocr Metab Disord."},{"key":"B90","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ejim.2024.05.006","article-title":"Pharmacotherapy for older people with obesity","volume":"130","author":"Boyle","year":"2024","journal-title":"Eur J Intern Med."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1001\/jama.2025.14092","article-title":"Semaglutide and tirzepatide in patients with heart failure with preserved ejection fraction","volume":"334","author":"Kr\u00fcger","year":"2025","journal-title":"JAMA"},{"key":"B92","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.clnu.2021.11.014","article-title":"Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement","volume":"41","author":"Donini","year":"2022","journal-title":"Clin Nutr."},{"key":"B93","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s13668-025-00649-w","article-title":"Impact of GLP- 1 receptor agonist therapy in patients high risk for sarcopenia","volume":"14","author":"Memel","year":"2025","journal-title":"Curr Nutr Rep."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1002\/jpen.70013","article-title":"Body composition in patients with obesity-related heart failure with preserved ejection fraction: a comparison study","volume":"49","author":"Salmons","year":"2025","journal-title":"JPEN J Parenter Enter Nutr."},{"key":"B95","doi-asserted-by":"publisher","first-page":"892","DOI":"10.4070\/kcj.2024.0366","article-title":"Prevalence, pathophysiology, and prognostic importance of malnutrition risk in early-stage patients with heart failure and preserved ejection fraction","volume":"55","author":"Tani","year":"2025","journal-title":"Korean Circ J."},{"key":"B96","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41366-024-01529-z","article-title":"Obesity pharmacotherapy in older adults: a narrative review of evidence","volume":"49","author":"Henney","year":"2025","journal-title":"Int J Obes."},{"key":"B97","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.2337\/dbi25-0004","article-title":"Treating sarcopenic obesity in the era of incretin therapies: perspectives and challenges","volume":"74","author":"Chen","year":"2025","journal-title":"Diabetes"},{"key":"B98","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.clnu.2024.12.004","article-title":"Beyond fat: does semaglutide affect lean mass?","volume":"44","author":"Jamialahmadi","year":"2025","journal-title":"Clin Nutr."},{"key":"B99","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.cardfail.2024.06.007","article-title":"Long-term changes in body composition and exercise capacity following calorie restriction and exercise training in older patients with obesity and heart failure with preserved ejection fraction","volume":"31","author":"Upadhya","year":"2025","journal-title":"J Card Fail."},{"key":"B100","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1001\/jamacardio.2025.0103","article-title":"Novel controlled metabolic accelerator for obesity-related HFpEF: the HuMAIN-HFpEF randomized clinical trial","volume":"10","author":"Pandey","year":"2025","journal-title":"JAMA Cardiol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.jacc.2024.06.001","article-title":"Efficacy of semaglutide by sex in obesity-related heart failure with preserved ejection fraction","volume":"84","author":"Verma","year":"2024","journal-title":"J Am Coll Cardiol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jacc.2024.04.038","article-title":"Semaglutide and NYHA functional class in obesity-related heart failure with preserved ejection fraction","volume":"84","author":"Schou","year":"2024","journal-title":"J Am Coll Cardiol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1016\/j.jacc.2024.08.021","article-title":"Effect of semaglutide on cardiac structure and function in patients with obesity-related heart failure","volume":"84","author":"Solomon","year":"2024","journal-title":"J Am Coll Cardiol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"afag034","DOI":"10.1093\/ageing\/afag034","article-title":"Age- and sex-specific muscle health cut-offs improve prognostic accuracy in older patients with heart failure: a secondary analysis of a nationwide, multicenter cohort registry","volume":"55","author":"Miki","year":"2026","journal-title":"Age Ageing"},{"key":"B105","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.jchf.2025.03.025","article-title":"Facts and fallacies of body composition analysis in heart failure","volume":"13","author":"Yuzefpolskaya","year":"2025","journal-title":"JACC Heart Fail."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1161\/CIRCRESAHA.124.325614","article-title":"Skeletal muscle as a mediator of interorgan crosstalk during exercise: implications for aging and obesity","volume":"136","author":"Shero","year":"2025","journal-title":"Circ Res."},{"key":"B107","doi-asserted-by":"publisher","first-page":"131553","DOI":"10.1016\/j.ijcard.2023.131553","article-title":"Contribution of reduced skeletal muscle perfusion reserve to exercise intolerance in heart failure with preserved ejection fraction","volume":"395","author":"Serafin","year":"2024","journal-title":"Int J Cardiol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/j.jacbts.2024.07.009","article-title":"Exercise therapy rescues skeletal muscle dysfunction and exercise intolerance in cardiometabolic HFpEF","volume":"9","author":"Quiriarte","year":"2024","journal-title":"JACC Basic Transl Sci."},{"key":"B109","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jacbts.2023.09.014","article-title":"Caloric restriction rejuvenates skeletal muscle growth in heart failure with preserved ejection fraction","volume":"9","author":"Espino-Gonzalez","year":"2024","journal-title":"JACC Basic Transl Sci."},{"key":"B110","doi-asserted-by":"publisher","first-page":"e012350","DOI":"10.1161\/CIRCHEARTFAILURE.124.012350","article-title":"Musclin counteracts skeletal muscle dysfunction and exercise intolerance in heart failure with preserved ejection fraction","volume":"18","author":"Saw","year":"2025","journal-title":"Circ Heart Fail."},{"key":"B111","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41574-022-00641-2","article-title":"Exerkines in health, resilience and disease","volume":"18","author":"Chow","year":"2022","journal-title":"Nat Rev Endocrinol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"e009124","DOI":"10.1161\/CIRCHEARTFAILURE.121.009124","article-title":"Impact of different training modalities on molecular alterations in skeletal muscle of patients with heart failure with preserved ejection fraction: a substudy of the OptimEx trial","volume":"15","author":"Winzer","year":"2022","journal-title":"Circ Heart Fail."},{"key":"B113","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41591-024-03342-7","article-title":"Combined endurance and resistance exercise training in heart failure with preserved ejection fraction: a randomized controlled trial","volume":"31","author":"Edelmann","year":"2025","journal-title":"Nat Med."},{"key":"B114","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.1093\/eurheartj\/ehae479","article-title":"Ferric carboxymaltose and exercise capacity in heart failure with preserved ejection fraction and iron deficiency: the FAIR-HFpEF trial","volume":"45","author":"Von Haehling","year":"2024","journal-title":"Eur Heart J."},{"key":"B115","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/j.jacbts.2024.10.009","article-title":"Mechanisms of skeletal muscle dysfunction in cardiometabolic HFpEF and its reversal with exercise training","volume":"9","author":"Upadhya","year":"2024","journal-title":"JACC Basic Transl Sci."},{"key":"B116","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s10741-024-10439-1","article-title":"Lifestyle interventions in cardiometabolic HFpEF: dietary and exercise modalities","volume":"30","author":"Vacca","year":"2024","journal-title":"Heart Fail Rev."},{"key":"B117","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1001\/jamainternmed.2025.1794","article-title":"Integrating diet and physical activity when prescribing GLP-1s\u2014lifestyle factors remain crucial","volume":"185","author":"Mehrtash","year":"2025","journal-title":"JAMA Intern Med."},{"key":"B118","doi-asserted-by":"publisher","first-page":"100522","DOI":"10.1016\/j.advnut.2025.100522","article-title":"Nutritional challenges of incretin-based obesity management medications: implications for clinical practice","volume":"16","author":"Ben-Porat","year":"2025","journal-title":"Adv Nutr."},{"key":"B119","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1002\/oby.24067","article-title":"Nutritional considerations with antiobesity medications","volume":"32","author":"Almandoz","year":"2024","journal-title":"Obesity"},{"key":"B120","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.clnu.2025.02.022","article-title":"Dietary protein intake, protein sources & distribution patterns in community-dwelling older adults: a harmonized analysis of eight studies","volume":"47","author":"Koopmans","year":"2025","journal-title":"Clin Nutr."},{"key":"B121","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12937-025-01279-2","article-title":"Is higher protein intake during weight loss interventions in older adults associated with improved outcomes? A secondary data analysis of three randomised controlled trials","volume":"25","author":"Eglseer","year":"2026","journal-title":"Nutr J."},{"key":"B122","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1002\/jcsm.12922","article-title":"Systematic review and meta-analysis of protein intake to support muscle mass and function in healthy adults","volume":"13","author":"Nunes","year":"2022","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"B123","doi-asserted-by":"publisher","first-page":"e010161","DOI":"10.1161\/CIRCHEARTFAILURE.122.010161","article-title":"A randomized, controlled trial of resistance training added to caloric restriction plus aerobic exercise training in obese heart failure with preserved ejection fraction","volume":"16","author":"Brubaker","year":"2023","journal-title":"Circ Heart Fail."},{"key":"B124","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12933-023-01765-z","article-title":"Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial","volume":"22","author":"Sandsdal","year":"2023","journal-title":"Cardiovasc Diabetol."},{"key":"B125","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/dom.15829","article-title":"Opportunities to optimize lifestyle interventions in combination with glucagon-like peptide-1-based therapy","volume":"26","author":"Dash","year":"2024","journal-title":"Diabetes Obes Metab."},{"key":"B126","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.jand.2024.10.023","article-title":"Incretin-based therapies and lifestyle interventions: the evolving role of registered dietitian nutritionists in obesity care","volume":"125","author":"Gigliotti","year":"2025","journal-title":"J Acad Nutr Diet."},{"key":"B127","doi-asserted-by":"publisher","first-page":"e243604","DOI":"10.1001\/jamanetworkopen.2024.3604","article-title":"Sarcopenia and sarcopenic obesity and mortality among older people","volume":"7","author":"Benz","year":"2024","journal-title":"JAMA Netw Open"},{"key":"B128","doi-asserted-by":"publisher","first-page":"104486","DOI":"10.1016\/j.cdnut.2024.104486","article-title":"Sculpting success: the importance of diet and physical activity to support skeletal muscle health during weight loss with new generation anti-obesity medications","volume":"8","author":"Grosicki","year":"2024","journal-title":"Curr Dev Nutr."},{"key":"B129","doi-asserted-by":"publisher","first-page":"e13960","DOI":"10.1111\/obr.13960","article-title":"Missing the target: a scoping review of the use of percent weight loss for obesity management","volume":"26","author":"Sherifali","year":"2025","journal-title":"Obes Rev."},{"key":"B130","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1016\/j.jacc.2024.08.028","article-title":"Inflammation in obesity-related HFpEF: the STEP-HFpEF program","volume":"84","author":"Verma","year":"2024","journal-title":"J Am Coll Cardiol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jacc.2024.04.022","article-title":"Semaglutide and NT-proBNP in obesity-related HFpEF: insights from the STEP-HFpEF program","volume":"84","author":"Petrie","year":"2024","journal-title":"J Am Coll Cardiol."},{"key":"B132","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S2213-8587(24)00304-8","article-title":"Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA1c levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial","volume":"13","author":"Davies","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B133","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1016\/j.jacc.2024.08.023","article-title":"Atrial fibrillation and semaglutide effects in obesity-related heart failure with preserved ejection fraction: STEP-HFpEF program","volume":"84","author":"Verma","year":"2024","journal-title":"J Am Coll Cardiol."},{"key":"B134","doi-asserted-by":"publisher","first-page":"102665","DOI":"10.1016\/j.xcrm.2026.102665","article-title":"Weight loss with GLP-1 medicines does not result in a disproportionate loss of muscle mass or function in obese mice and humans","volume":"7","author":"Langer","year":"2026","journal-title":"Cell Rep Med."},{"key":"B135","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1136\/bjsports-2024-108748","article-title":"Cardiorespiratory fitness, body mass index and mortality: a systematic review and meta-analysis","volume":"59","author":"Weeldreyer","year":"2025","journal-title":"Br J Sports Med."},{"key":"B136","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.1038\/s41591-025-03978-z","article-title":"A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults","volume":"31","author":"McGowan","year":"2025","journal-title":"Nat Med."},{"key":"B137","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.jacc.2025.05.024","article-title":"2025 concise clinical guidance: an ACC expert consensus statement on medical weight management for optimization of cardiovascular health: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"86","author":"Gilbert","year":"2025","journal-title":"J Am Coll Cardiol."},{"key":"B138","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.jacc.2022.02.025","article-title":"Nutrition assessment and dietary interventions in heart failure","volume":"79","author":"Driggin","year":"2022","journal-title":"J Am Coll Cardiol."},{"key":"B139","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.3390\/nu16172853","article-title":"Nutritional assessment in outpatients with heart failure","volume":"16","author":"L\u00f3pez Guill\u00e9n","year":"2024","journal-title":"Nutrients"},{"key":"B140","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/S0140-6736(25)02105-1","article-title":"GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits","volume":"407","author":"Nauck","year":"2026","journal-title":"Lancet."},{"key":"B141","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1001\/jamainternmed.2025.1133","article-title":"I Am taking a GLP-1 weight-loss medication\u2014what should I know?","volume":"185","author":"Mehrtash","year":"2025","journal-title":"JAMA Intern Med."},{"key":"B142","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/dom.16364","article-title":"Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies","volume":"27","author":"Thomsen","year":"2025","journal-title":"Diabetes Obes Metab."},{"key":"B143","doi-asserted-by":"publisher","first-page":"3254","DOI":"10.1093\/eurheartj\/ehae322","article-title":"Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trials","volume":"45","author":"Shah","year":"2024","journal-title":"Eur Heart J."},{"key":"B144","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/s41591-024-03374-z","article-title":"Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial","volume":"31","author":"Borlaug","year":"2025","journal-title":"Nat Med."},{"key":"B145","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","article-title":"Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials","volume":"13","author":"Badve","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B146","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1038\/s41591-023-02597-w","article-title":"Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial","volume":"29","author":"Wadden","year":"2023","journal-title":"Nat Med."},{"key":"B147","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1001\/jama.2025.24288","article-title":"World health organization guideline on the use and indications of glucagon-like peptide-1 therapies for the treatment of obesity in adults","volume":"335","author":"Celletti","year":"2026","journal-title":"JAMA"},{"key":"B148","doi-asserted-by":"publisher","first-page":"E797","DOI":"10.1503\/cmaj.250502","article-title":"Pharmacotherapy for obesity management in adults: 2025 clinical practice guideline update","volume":"197","author":"Pedersen","year":"2025","journal-title":"Can Med Assoc J."},{"key":"B149","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1002\/oby.24027","article-title":"Physiology of the weight-loss plateau in response to diet restriction, GLP-1 receptor agonism, and bariatric surgery","volume":"32","author":"Hall","year":"2024","journal-title":"Obesity"},{"key":"B150","doi-asserted-by":"publisher","first-page":"5064","DOI":"10.1111\/dom.16554","article-title":"Weight reduction over time in tirzepatide-treated participants by early weight loss response: post hoc analysis in SURMOUNT-1","volume":"27","author":"Ard","year":"2025","journal-title":"Diabetes Obes Metab."},{"key":"B151","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.eprac.2025.07.017","article-title":"American association of clinical endocrinology consensus statement: algorithm for the evaluation and treatment of adults with obesity\/adiposity-based chronic disease \u2013 2025 update","volume":"31","author":"Nadolsky","year":"2025","journal-title":"Endocr Pract."},{"key":"B152","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1002\/oby.24172","article-title":"GLP1Ra-based therapies and DXA-acquired musculoskeletal health outcomes: a focused meta-analysis of placebo-controlled trials","volume":"33","author":"Beavers","year":"2025","journal-title":"Obesity"},{"key":"B153","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/dom.16046","article-title":"Association between weight reduction achieved with tirzepatide and quality of life in adults with obesity: results from the SURMOUNT-1 study","volume":"27","author":"Gudzune","year":"2025","journal-title":"Diabetes Obes Metab."},{"key":"B154","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.eprac.2024.06.009","article-title":"Weight-reduction preferences among OBSERVE study participants with obesity or overweight: opportunities for shared decision-making","volume":"30","author":"Gudzune","year":"2024","journal-title":"Endocr Pract."},{"key":"B155","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1002\/oby.70058","article-title":"Reasons for discontinuation of obesity pharmacotherapy with semaglutide or tirzepatide in clinical practice","volume":"33","author":"Gasoyan","year":"2025","journal-title":"Obesity"},{"key":"B156","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1111\/dom.14725","article-title":"Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension","volume":"24","author":"Wilding","year":"2022","journal-title":"Diabetes Obes Metab."},{"key":"B157","doi-asserted-by":"publisher","first-page":"e085304","DOI":"10.1136\/bmj-2025-085304","article-title":"Weight regain after cessation of medication for weight management: systematic review and meta-analysis","volume":"392","author":"West","year":"2026","journal-title":"BMJ"},{"key":"B158","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1016\/S0140-6736(26)00656-2","article-title":"Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial","volume":"407","author":"Horn","year":"2026","journal-title":"Lancet."},{"key":"B159","doi-asserted-by":"publisher","first-page":"102475","DOI":"10.1016\/j.eclinm.2024.102475","article-title":"Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial","volume":"69","author":"Jensen","year":"2024","journal-title":"eClinicalMedicine"},{"key":"B160","doi-asserted-by":"publisher","first-page":"4795","DOI":"10.1111\/dom.70660","article-title":"Obesity treatments and weight changes in clinical practice after discontinuation of semaglutide or tirzepatide","volume":"28","author":"Gasoyan","year":"2026","journal-title":"Diabetes Obes Metab."},{"key":"B161","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.cardfail.2024.01.015","article-title":"The effectiveness of lifestyle interventions in heart failure with preserved ejection fraction: a systematic review and network meta-analysis","volume":"30","author":"Walters","year":"2024","journal-title":"J Card Fail."},{"key":"B162","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1093\/eurjcn\/zvac114","article-title":"What are the outcomes of dietary interventions in heart failure with preserved ejection fraction? A systematic review and meta-analysis","volume":"22","author":"Forsyth","year":"2023","journal-title":"Eur J Cardiovasc Nurs."},{"key":"B163","doi-asserted-by":"publisher","first-page":"e022930","DOI":"10.1161\/JAHA.121.022930","article-title":"Pragmatic weight management program for patients with obesity and heart failure with preserved ejection fraction","volume":"10","author":"El Hajj","year":"2021","journal-title":"J Am Heart Assoc."},{"key":"B164","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1016\/S0140-6736(22)00369-5","article-title":"Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial","volume":"399","author":"Ezekowitz","year":"2022","journal-title":"Lancet."},{"key":"B165","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.cardfail.2024.01.005","article-title":"Malnutrition and sarcopenia as reasons for caution with GLP-1 receptor agonist use in HFpEF","volume":"30","author":"Driggin","year":"2024","journal-title":"J Card Fail."},{"key":"B166","doi-asserted-by":"publisher","first-page":"e699","DOI":"10.1161\/CIR.0000000000001122","article-title":"Supervised exercise training for chronic heart failure with preserved ejection fraction: a scientific statement from the American heart association and American college of cardiology","volume":"147","author":"Sachdev","year":"2023","journal-title":"Circulation"},{"key":"B167","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1161\/CIR.0000000000001289","article-title":"Core components of cardiac rehabilitation programs: 2024 update: a scientific statement from the American Heart Association and the American Association of Cardiovascular and Pulmonary Rehabilitation","volume":"150","author":"Brown","year":"2024","journal-title":"Circulation"},{"key":"B168","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.clnu.2025.03.018","article-title":"The GLIM consensus approach to diagnosis of malnutrition: a 5-year update","volume":"49","author":"Cederholm","year":"2025","journal-title":"Clin Nutr."},{"key":"B169","doi-asserted-by":"publisher","first-page":"120","DOI":"10.7570\/jomes25010","article-title":"The critical role of body composition assessment in advancing research and clinical health risk assessment across the lifespan","volume":"34","author":"Bennett","year":"2025","journal-title":"J Obes Metab Syndr."},{"key":"B170","doi-asserted-by":"publisher","first-page":"e13841","DOI":"10.1002\/jcsm.13841","article-title":"Sarcopenia in ageing and chronic illness: trial endpoints and regulatory issues","volume":"16","author":"Von Haehling","year":"2025","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"B171","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1007\/s40279-025-02386-0","article-title":"Physical fitness with exercise and GLP-1 receptor agonist treatment alone or combined after diet-induced weight loss: a secondary analysis of a randomized controlled trial in adults with obesity","volume":"56","author":"Jensen","year":"2026","journal-title":"Sports Med"},{"key":"B172","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1161\/CIRCULATIONAHA.124.072158","article-title":"Patient-reported outcomes as end points in heart failure trials","volume":"151","author":"Butler","year":"2025","journal-title":"Circulation"},{"key":"B173","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.jacbts.2025.04.003","article-title":"Derisking phase II clinical trials in heart failure: a position paper from JACC: basic to translational science and the heart failure collaboratory","volume":"10","author":"Mann","year":"2025","journal-title":"JACC Basic Transl Sci."},{"key":"B174","doi-asserted-by":"publisher","first-page":"4063","DOI":"10.1093\/eurheartj\/ehae508","article-title":"Obesity and cardiovascular disease: an ESC clinical consensus statement","volume":"45","author":"Koskinas","year":"2024","journal-title":"Eur Heart J."},{"key":"B175","doi-asserted-by":"publisher","first-page":"e70079","DOI":"10.1111\/obr.70079","article-title":"Nutrition strategies for next-generation incretin therapies: a systematic scoping review of the current evidence","volume":"27","author":"Spreckley","year":"2026","journal-title":"Obes Rev."},{"key":"B176","doi-asserted-by":"publisher","first-page":"100399","DOI":"10.1016\/j.advnut.2025.100399","article-title":"Medical nutrition therapy (MNT) evidence update: comparative effectiveness of dietary programs for reducing mortality and cardiovascular events in adults with increased cardiovascular disease risk","volume":"16","author":"Esmaeilinezhad","year":"2025","journal-title":"Adv Nutr."},{"key":"B177","doi-asserted-by":"publisher","first-page":"156219","DOI":"10.1016\/j.jand.2025.10.010","article-title":"The effectiveness of medical nutrition therapy in prevention and treatment of chronic disease: a position paper of the academy of nutrition and dietetics","volume":"126","author":"Moloney","year":"2026","journal-title":"J Acad Nutr Diet."},{"key":"B178","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1002\/oby.23930","article-title":"Physical activity in the new era of antiobesity medications","volume":"32","author":"Jakicic","year":"2024","journal-title":"Obesity"},{"key":"B179","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1161\/CIR.0000000000001343","article-title":"A systematic review of \u201cfood is medicine\u201d randomized controlled trials for noncommunicable disease in the United States: a scientific statement from the American heart association","volume":"152","author":"Seligman","year":"2025","journal-title":"Circulation"},{"key":"B180","doi-asserted-by":"publisher","first-page":"4747","DOI":"10.1111\/dom.16512","article-title":"Incretin-based therapies for individuals with obesity and heart failure with mildly reduced or preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials","volume":"27","author":"Costa","year":"2025","journal-title":"Diabetes Obes Metab."},{"key":"B181","doi-asserted-by":"publisher","first-page":"7030","DOI":"10.1111\/dom.70102","article-title":"Efficacy of GLP-1 receptor agonists in patients with obesity and heart failure with preserved ejection fraction: a systematic review and meta-analysis of randomised controlled trials","volume":"27","author":"Talavera","year":"2025","journal-title":"Diabetes Obes Metab."},{"key":"B182","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/dom.15728","article-title":"Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies","volume":"26","author":"Neeland","year":"2024","journal-title":"Diabetes Obes Metab."},{"key":"B183","doi-asserted-by":"publisher","first-page":"5503","DOI":"10.1111\/dom.15913","article-title":"Glucagon-like peptide-1 receptor agonist-based agents and weight loss composition: filling the gaps","volume":"26","author":"Dubin","year":"2024","journal-title":"Diabetes Obes Metab."}],"updated-by":[{"DOI":"10.3389\/fnut.2026.1970493","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000}}],"container-title":["Frontiers in Nutrition"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2026.1914155\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T13:42:43Z","timestamp":1788270163000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2026.1914155\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":183,"alternative-id":["10.3389\/fnut.2026.1914155"],"URL":"https:\/\/doi.org\/10.3389\/fnut.2026.1914155","relation":{},"ISSN":["2296-861X"],"issn-type":[{"value":"2296-861X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"article-number":"1914155"}}